Literature DB >> 10718632

Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals.

H P Misra1, C Rabideau.   

Abstract

Pirfenidone (Pf), a new broad-spectrum anti-fibrotic agent, is known to offer protection against lung fibrosis in vivo in laboratory animals, and against mitogenesis and collagen formation by human lung fibroblasts in vitro. Because reactive oxygen species are thought to be involved in these events, we investigated the mechanism(s) by which Pf ameliorates oxidative stress and its effects on NADPH-dependent lipid peroxidation. Pf has been shown to cause inhibit NADPH-dependent lipid peroxidation in sheep liver microsomes in a dose-dependent manner. The concentration of Pf required to cause 50% inhibition of lipid peroxidation was approximately 6 mM. Pf was found to be ineffective as a superoxide radical scavenger. Pf was also ineffective in decomposing H2O2 and chelating iron. In deoxyribose degradation assays, Pf was a potent scavenger of hydroxyl radicals with a rate constant of 5.4 x 10(9) M(-1) sec(-1). EPR spectroscopy in combination with spin trapping techniques, using a Fenton type reaction and DMPO as a spin-trapping agent, Pf scavenged hydroxyl radicals in a dose-dependent manner. The concentration of Pf required to inhibit 50% signal height was approximately 2.5 mM. Because iron was used in the Fenton reaction, the ability of Pf in chelating iron was verified in a fluorescent competitive assay using calcein as the fluorescent probe. Pf up to 10 mM concentration was ineffective in chelating either Fe2+ or Fe3+ in this system. We propose that Pf exerts its beneficial effects, at least in part, through its ability to scavenge toxic hydroxyl radicals.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10718632     DOI: 10.1023/a:1007023532508

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  47 in total

1.  Effect of the hydroxyl radical on fibroblast-mediated collagen remodelling in vitro.

Authors:  S Arisawa; T Arisawa; M Ohashi; Y Nitta; T Ikeya; J Asai
Journal:  Clin Exp Pharmacol Physiol       Date:  1996-03       Impact factor: 2.557

2.  Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis.

Authors:  P Rust; I Eichler; S Renner; I Elmadfa
Journal:  Int J Vitam Nutr Res       Date:  1998       Impact factor: 1.784

3.  Evidence for the involvement of the hydroxyl radical in the pathogenesis of excessive connective tissue proliferation in patients with tumor-endoprostheses.

Authors:  R Windhager; M Nemethova; S Mutsaers; S Lang; R Kotz; E Kitzmueller; G Lubec
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

4.  Increases in lung prolyl hydroxylase and superoxide dismutase activities during bleomycin-induced lung fibrosis in hamsters.

Authors:  S N Giri; H P Misra; D B Chandler; Z L Chen
Journal:  Exp Mol Pathol       Date:  1983-12       Impact factor: 3.362

Review 5.  Fibrogenic cytokines: the role of immune mediators in the development of scar tissue.

Authors:  E J Kovacs
Journal:  Immunol Today       Date:  1991-01

6.  Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice.

Authors:  J P Kehrer; S B Margolin
Journal:  Toxicol Lett       Date:  1997-02-07       Impact factor: 4.372

Review 7.  Oxidative damage and fibrogenesis.

Authors:  G Poli; M Parola
Journal:  Free Radic Biol Med       Date:  1997       Impact factor: 7.376

8.  Macrophage/fibroblast coculture induces macrophage inflammatory protein-1alpha production mediated by intercellular adhesion molecule-1 and oxygen radicals.

Authors:  M L Steinhauser; S L Kunkel; C M Hogaboam; H Evanoff; R M Strieter; N W Lukacs
Journal:  J Leukoc Biol       Date:  1998-11       Impact factor: 4.962

9.  Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone.

Authors:  W C Cain; R W Stuart; D L Lefkowitz; J D Starnes; S Margolin; S S Lefkowitz
Journal:  Int J Immunopharmacol       Date:  1998-12

10.  Vitamin E dietary supplementation inhibits transforming growth factor beta 1 gene expression in the rat liver.

Authors:  M Parola; R Muraca; I Dianzani; G Barrera; G Leonarduzzi; P Bendinelli; R Piccoletti; G Poli
Journal:  FEBS Lett       Date:  1992-08-24       Impact factor: 4.124

View more
  31 in total

1.  A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model.

Authors:  J S Swaney; C Chapman; L D Correa; K J Stebbins; R A Bundey; P C Prodanovich; P Fagan; C S Baccei; A M Santini; J H Hutchinson; T J Seiders; T A Parr; P Prasit; J F Evans; D S Lorrain
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 2.  Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Treat Respir Med       Date:  2006

Review 3.  New pharmacological treatments for improving renal outcomes in diabetes.

Authors:  Anne-Emilie Declèves; Kumar Sharma
Journal:  Nat Rev Nephrol       Date:  2010-05-04       Impact factor: 28.314

4.  Redox Imbalance in Idiopathic Pulmonary Fibrosis: A Role for Oxidant Cross-Talk Between NADPH Oxidase Enzymes and Mitochondria.

Authors:  Carmen Veith; Agnes W Boots; Musa Idris; Frederik-Jan van Schooten; Albert van der Vliet
Journal:  Antioxid Redox Signal       Date:  2019-04-05       Impact factor: 8.401

Review 5.  Pirfenidone: in idiopathic pulmonary fibrosis.

Authors:  Natalie J Carter
Journal:  Drugs       Date:  2011-09-10       Impact factor: 9.546

6.  Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B.

Authors:  Martha L Hale; Solomon B Margolin; Teresa Krakauer; Chad J Roy; Bradley G Stiles
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

Review 7.  Pirfenidone: an anti-fibrotic therapy for progressive kidney disease.

Authors:  Monique E Cho; Jeffrey B Kopp
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

8.  Oxidative Modifications of Protein Tyrosyl Residues Are Increased in Plasma of Human Subjects with Interstitial Lung Disease.

Authors:  Subramaniam Pennathur; Anuradha Vivekanandan-Giri; Morgan L Locy; Tejaswini Kulkarni; Degui Zhi; Lixia Zeng; Jaeman Byun; Joao A de Andrade; Victor J Thannickal
Journal:  Am J Respir Crit Care Med       Date:  2016-04-15       Impact factor: 21.405

9.  The multifaceted role of pirfenidone and its novel targets.

Authors:  José Macías-Barragán; Ana Sandoval-Rodríguez; Jose Navarro-Partida; Juan Armendáriz-Borunda
Journal:  Fibrogenesis Tissue Repair       Date:  2010-09-01

10.  Pirfenidone is renoprotective in diabetic kidney disease.

Authors:  Satish P RamachandraRao; Yanqing Zhu; Timothy Ravasi; Tracy A McGowan; Irene Toh; Stephen R Dunn; Shinichi Okada; Michael A Shaw; Kumar Sharma
Journal:  J Am Soc Nephrol       Date:  2009-07-02       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.